Pharmigene's earnings have been declining at an average annual rate of -30.8%, while the Biotechs industry saw earnings growing at 21.8% annually. Revenues have been growing at an average rate of 7.6% per year.
Key information
-30.78%
Earnings growth rate
-26.81%
EPS growth rate
Biotechs Industry Growth
12.22%
Revenue growth rate
7.56%
Return on equity
-26.22%
Net Margin
-36.52%
Last Earnings Update
31 Dec 2025
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Pharmigene makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
TPEX:7595 Revenue, expenses and earnings (TWD Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Dec 25
200
-73
71
41
30 Sep 25
175
-74
75
39
30 Jun 25
149
-76
79
37
31 Mar 25
133
-79
88
33
31 Dec 24
117
-83
97
30
30 Sep 24
122
-88
94
30
30 Jun 24
127
-93
90
30
31 Mar 24
130
-83
81
30
31 Dec 23
133
-73
71
30
30 Sep 23
133
-61
67
32
30 Jun 23
132
-48
64
33
31 Mar 23
133
-46
62
32
31 Dec 22
134
-43
59
30
30 Sep 22
129
-40
59
26
30 Jun 22
125
-37
58
22
31 Mar 22
127
-30
56
19
31 Dec 21
129
-23
53
15
30 Sep 21
120
-20
52
12
30 Jun 21
110
-16
52
9
31 Mar 21
106
-13
51
9
31 Dec 20
101
-11
49
9
30 Sep 20
97
-19
48
9
30 Jun 20
92
-27
47
9
31 Mar 20
79
-31
44
11
31 Dec 19
65
-35
41
12
31 Dec 18
78
-13
29
11
31 Dec 17
55
-8
16
8
Quality Earnings: 7595 is currently unprofitable.
Growing Profit Margin: 7595 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 7595 is unprofitable, and losses have increased over the past 5 years at a rate of 30.8% per year.
Accelerating Growth: Unable to compare 7595's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 7595 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.5%).
Return on Equity
High ROE: 7595 has a negative Return on Equity (-26.22%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/06/23 12:58
End of Day Share Price
2026/06/23 00:00
Earnings
2025/12/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pharmigene, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.